trending Market Intelligence /marketintelligence/en/news-insights/trending/Tg-TvBM6KiZ9DqWkjMZUaA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Nuvectra applies for US FDA approval of sacral nerve stimulation system

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Nuvectra applies for US FDA approval of sacral nerve stimulation system

Nuvectra Corp. submitted a pre-market approval application to the U.S. FDA for Virtis, its sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

The pre-market approval application, along with a submission to CE Mark authorities, positions the company to release the system in the European market by the end of 2017 and to begin commercialization efforts in the U.S. sometime in 2018, pending timely regulatory approval from each authority.